Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
View Patent ↗The present invention provides methods for treating or limiting development of age-related macular degeneration, as well as methods for identifying compound suitable for such use.
1. A method for treating age-related macular degeneration (AMD), comprising administering to a subject with AMD an amount of an agonist of the OA1 receptor selected from the group consisting of L-DOPA, an L-DOPA analogue, and pharmaceutically acceptable salts thereof, effective for treating AMD.
2. The method of claim 1 , wherein the agonist comprises L-DOPA, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the L-DOPA analogue comprises an L-DOPA prodrug, or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the L-DOPA prodrug comprises an L-DOPA ester, or a pharmaceutically acceptable salt thereof.
5. The method of claim 3 , wherein the L-DOPA prodrug comprises a bile acid conjugate of L-DOPA, or a pharmaceutically acceptable salt thereof.
6. The method of claim 3 wherein the L-DOPA prodrug comprises a di- or tri-peptide L-DOPA analogue, or a pharmaceutically acceptable salt thereof.
7. The method claim 1 , wherein the subject is over the age of 60.
8. The method of claim 1 , wherein the subject has wet AMD.
9. The method of claim 1 , wherein the subject has dry AMD.
10. The method of claim 1 , further comprising administering to the subject a combination of a vitamin C source, a vitamin E source, a beta-carotene source, a zinc source, and a copper source.
11. The method of claim 10 , comprising administering
between 450 mg and 600 mg vitamin C;
between 400 IU and 540 IU vitamin E;
between 17.2 mg and 28 mg beta-carotene;
between 68 mg and 100 mg zinc; and
between 1.6 mg and 2.4 mg copper.
12. The method claim 2 , wherein the subject is over the age of 60.
13. The method of claim 2 , wherein the subject has wet AMD.
14. The method of claim 2 , wherein the subject has dry AMD.
15. The method of claim 2 , further comprising administering to the subject a combination of a vitamin C source, a vitamin E source, a beta-carotene source, a zinc source, and a copper source.
16. The method of claim 15 , comprising administering
between 450 mg and 600 mg vitamin C;
between 400 IU and 540 IU vitamin E;
between 17.2 mg and 28 mg beta-carotene;
between 68 mg and 100 mg zinc; and
between 1.6 mg and 2.4 mg copper.